CLU — Clusterin (Apolipoprotein J)
Symbol	CLU
Full Name	Clusterin (Apolipoprotein J, ApoJ)
Chromosome	8p21.1
NCBI Gene	1115
Ensembl	ENSG00000120885
OMIM	185551
UniProt	P10909
Diseases	[Alzheimer's Disease](/diseases/alzheimers-disease), [Huntington's Disease](/diseases/huntingtons-disease), ALS
Expression	Hippocampus, Cortex, Basal ganglia, Cerebellum
Key Variants
rs11136000 (protective, OR ~0.86) rs2279590 (eQTL) rs42039 (coding)
Associated Diseases	ALZHEIMER, ALZHEIMER'S, ALZHEIMER'S DISEASE, Aging, Als
KG Connections	341 edges

CLU — Clusterin (Apolipoprotein J)

Introduction

CLU (also known as Clusterin or Apolipoprotein J, ApoJ) is a gene located on chromosome 8p21.1 that encodes a highly conserved multifunctional glycoprotein. CLU was first identified as a significant genetic risk factor for late-onset Alzheimer’s disease (AD) in the landmark genome-wide association study (GWAS) published in 2009, alongside PICALM and CR1 ^{1Genome-wide association study identifies variants at CLU and CR1 associated2009 · Nat Genet · DOI 10.1038/ng.439Open reference}. The protective variant rs11136000 has an odds ratio of approximately 0.86, meaning carriers have approximately 14% reduced risk of developing AD.

Clusterin is one of the most abundant proteins in the brain and is involved in numerous physiological processes including lipid transport, complement regulation, apoptosis inhibition, and protein homeostasis. Its role in AD pathogenesis is particularly significant due to its ability to bind amyloid-beta (Aβ) and facilitate its clearance from the brain.

---

Gene Structure and Expression

Genomic Organization

The CLU gene spans approximately 16 kb on chromosome 8p21.1 (coordinates: chr8:27,456,000-27,472,000, GRCh38). It consists of 9 exons encoding a precursor protein that undergoes extensive post-translational modification. The gene uses alternative transcription start sites and alternative splicing to produce multiple isoforms with distinct cellular localizations.

Brain Expression

Clusterin is widely expressed throughout the brain:

• Hippocampus — highest expression in CA1-CA3 pyramidal neurons and dentate gyrus granule cells

• Cerebral cortex — strong expression in layers II-IV, particularly in pyramidal neurons

• Basal ganglia — moderate expression in striatum

• Cerebellum — expression in Purkinje cells

• Brainstem and thalamus — lower but detectable expression

Cellular Distribution

In the brain, clusterin is produced by multiple cell types:

• Neurons — principal producers in the healthy brain, both as secreted and nuclear isoforms

• Astrocytes — significantly upregulated in reactive astrocytes in AD and other pathological conditions

• Oligodendrocytes — associated with myelin sheaths

• Microglia — increased expression in activated microglia

Expression data is available from the Allen Human Brain Atlas.

Allen Brain Atlas Data

Gene Expression

Clusterin (CLU) shows widespread expression in the brain:

• Neurons - High expression in pyramidal neurons throughout cortex and hippocampus

• Astrocytes - Strong expression in reactive astrocytes in AD

• Oligodendrocytes - Moderate expression

• Microglia - Upregulated in activated microglia

Single-Cell Expression

Single-cell RNA-seq data from the Allen Brain Atlas shows:

• Excitatory neurons - High expression

• Inhibitory neurons - Moderate expression

• Astrocytes - Variable, higher in reactive states

• Microglia - Increased in disease states

Brain Region Expression Levels

Region	Expression Level	Data Source
Cortex	Very High	Human MTG
Hippocampus	Very High	Mouse Brain
Cerebellum	High	Mouse Brain
Striatum	Medium	Mouse Brain

External Resources

• Allen Human Brain Atlas - CLU

• Allen Mouse Brain Atlas - Clu

• Allen Cell Type Atlas - CLU

---

Protein Structure and Function

Domain Architecture

Clusterin is a 449-amino acid glycoprotein with distinct structural domains:

1. Signal Peptide (1-22) — Enables secretion via the classical secretory pathway

2. N-terminal Domain (23-227) — Contains complement-binding regions (CBRs) that interact with complement proteins. This domain is responsible for the complement regulatory function of clusterin.

3. C-terminal Domain (228-427) — The chaperone activity domain that binds misfolded proteins including Aβ. Contains a methionine-rich region that contributes to antioxidant properties.

4. Heavily Glycosylated Regions — Five N-linked glycosylation sites are essential for secretion, stability, and function.

Post-translational Modifications

Clusterin undergoes several important post-translational modifications:

• Glycosylation — Essential for secretion and function; affects protein stability and receptor interactions

• Proteolytic Cleavage — The secreted form is cleaved at position 205 to generate alpha (23-205) and beta (206-449) subunits that are linked by disulfide bonds

• Phosphorylation — Affects receptor interactions and cellular signaling

Alternative Splicing and Isoforms

Multiple isoforms of clusterin exist:

• Secreted Clusterin (sCLU) — The predominant form, secreted into extracellular fluids including cerebrospinal fluid (CSF) and plasma

• Nuclear Clusterin (nCLU) — Alternative splicing produces an intracellular isoform (lacking the signal peptide) that localizes to the nucleus and has pro-apoptotic functions

---

Normal Physiological Functions

Lipid Transport

As an apolipoprotein, clusterin participates in:

• Cholesterol transport — Mediates reverse cholesterol transport from peripheral tissues to the liver

• Lipid droplet formation — Associates with lipid storage organelles

• Membrane repair — Facilitates plasma membrane damage repair

• Myelin maintenance — Supports oligodendrocyte function and myelin integrity

Complement Regulation

Clusterin is a potent regulator of the complement system:

• Complement inhibition — Binds to C5b-7 and C5b-8 complexes, preventing formation of the membrane attack complex

• Inflammatory modulation — Reduces complement-mediated inflammatory damage in the brain

Apoptosis Regulation

Clusterin inhibits both caspase-dependent and caspase-independent cell death pathways:

• Intrinsic pathway — Blocks Bax translocation to mitochondria, preventing cytochrome c release

• Extrinsic pathway — Inhibits caspase-8 activation

• ER stress — Modulates the unfolded protein response

• Necroptosis — Reduces MLKL phosphorylation

Molecular Chaperone Activity

The defining function of clusterin is its ability to act as a molecular chaperone:

• Binds to misfolded proteins to prevent aggregation

• Prevents toxic oligomer formation

• Facilitates clearance of aberrant proteins through receptor-mediated endocytosis

Ferroptosis Protection

Emerging research has identified clusterin as a key protector against ferroptosis, an iron-dependent form of programmed cell death ^{2Clusterin protects against ferroptosis in Alzheimer's disease2023 · Cell Death Discov · DOI 10.1038/s41420-023-01256-w · PMID 36894631Open reference}:

• Lipid Peroxidation Inhibition — Clusterin scavenges lipid reactive oxygen species (ROS)

• Iron Metabolism — Modulates cellular iron homeostasis through ferritin regulation

• GPX4 Interaction — May support glutathione peroxidase 4 (GPX4) function

• Neuroprotection — Prevents iron-induced neuronal death in AD models

Mitochondrial Function

Clusterin supports mitochondrial health:

• Mitochondrial Membrane Stability — Preserves mitochondrial membrane potential

• ATP Production — Supports optimal mitochondrial function

• Apoptosis Prevention — Blocks mitochondrial apoptosis pathways

• Mitophagy Regulation — Modulates removal of damaged mitochondria

• Autophagy Regulation — Clusterin regulates autophagy and lysosomal function in AD, supporting clearance of protein aggregates ^{3Clusterin regulates autophagy and lysosomal function in Alzheimer's disease2023 · Autophagy · DOI 10.1080/15548627.2023.2247912 · PMID 37452189Open reference}

APOE-Dependent Effects

Clusterin interacts with APOE in an isoform-dependent manner:

• ApoE4 carriers show reduced clusterin-mediated Aβ clearance compared to ApoE3

• Combined APOE4 and specific CLU variants have synergistic effects on AD risk

• Clusterin may compensate for reduced ApoE4 function in Aβ clearance ^{4ApoE isoform-dependent effects of clusterin on amyloid-beta aggregation2023 · J Biol Chem · DOI 10.1016/j.jbc.2023.104870 · PMID 37253214Open reference}

---

Disease Associations

Alzheimer’s Disease — GWAS Evidence

CLU was identified as an AD risk locus in the landmark 2009 GWAS meta-analysis, representing one of the first novel loci beyond APOE to reach genome-wide significance ^{1Genome-wide association study identifies variants at CLU and CR1 associated2009 · Nat Genet · DOI 10.1038/ng.439Open reference5Genome-wide analysis of genetic loci associated with Alzheimer disease2010 · JAMA · DOI 10.1001/jama.2010.555Open reference}. The association has been robustly replicated across multiple independent cohorts.

Key Genetic Variants

• rs11136000 — The lead protective variant, located in an intronic region. The protective T allele is associated with reduced AD risk (OR ~0.86). This variant affects CLU expression levels through an expression quantitative trait locus (eQTL) effect.

• rs2279590 — An eQTL variant that affects CLU expression in brain tissue

• rs42039 — A coding variant that may influence protein function

These variants are associated with altered CLU expression, with protective alleles associated with higher clusterin levels. This suggests that increased clusterin expression is protective against AD, consistent with its role in Aβ clearance.

Population Genetics

• European ancestry — rs11136000-T allele frequency ~57% (protective)

• Asian ancestry — Similar patterns but somewhat weaker LD

• African ancestry — Different allele frequencies

Amyloid-beta Clearance

Clusterin plays a critical role in clearing amyloid-beta from the brain through multiple mechanisms ^{6Clusterin in Alzheimer''s disease: Mechanisms and therapeutic potential2019 · Acta Neuropathol · DOI 10.1007/s00401-019-02013-zOpen reference7Clusterin promotes amyloid clearance and the blood-brain barrier2012 · J Neurosci · DOI 10.1523/JNEUROSCI.1543-12.2012Open reference}:

1. Chaperone Activity — Clusterin’s beta chain binds Aβ peptides with high affinity, preventing their aggregation into toxic oligomers and plaques. This interaction is one of the most important therapeutic mechanisms being explored.

2. Receptor-mediated Uptake — Clusterin-Aβ complexes are cleared through LRP-1 and LRP-2 (megalin) receptor-mediated endocytosis at the blood-brain barrier (BBB), facilitating transport out of the CNS.

3. Proteolytic Degradation — Clusterin facilitates Aβ degradation by matrix metalloproteinases (MMPs) and other proteases.

4. Perivascular Drainage — Clusterin-Aβ complexes exit the brain via perivascular lymphatic drainage pathways, a major route for Aβ clearance.

Tau Pathology

Clusterin interacts with tau at multiple levels:

• Tau Binding — Clusterin directly binds to phosphorylated tau, influencing its aggregation propensity

• Tau Secretion — Neuronal release of tau is facilitated by clusterin, potentially enabling propagation of pathology

• Oligomer Neutralization — Clusterin neutralizes toxic tau oligomers before fibril formation

• Clearance Enhancement — Promotes extracellular tau clearance through proteolytic degradation

Synaptic Protection

Clusterin protects synaptic function in several ways:

• Synaptic Membrane Stability — Stabilizes lipid rafts at synaptic membranes

• Oxidative Stress Protection — Scavenges reactive oxygen species through its methionine-rich domain

• Calcium Homeostasis — Modulates calcium signaling in neurons

• Synaptic Plasticity — Supports long-term potentiation and memory consolidation

Neuroinflammation Regulation

Clusterin modulates neuroinflammatory responses ^{8"Clusterin mediates A\u03B2-induced neuroinflammation through NF-\u03BA\2022 · J Neuroinflammation · DOI 10.1186/s12974-022-02547-4 · PMID 36002987Open reference}:

• Complement Regulation — Inhibits complement activation, reducing inflammatory damage

• Cytokine Modulation — Regulates production of pro-inflammatory cytokines

• Microglial Activation — Influences microglial phenotype and phagocytic activity

• Peripheral Immune Cell Trafficking — Modulates immune cell entry into the CNS

• NF-κB Pathway Modulation — Clusterin-Aβ complexes activate anti-inflammatory signaling through NF-κB pathway inhibition

Other Neurodegenerative Diseases

Huntington’s Disease

• Mutant huntingtin promotes clusterin aggregation

• Clusterin may help clear mutant huntingtin aggregates

• Altered expression in HD brains

ALS and Frontotemporal Dementia

• Clusterin inclusions found in motor neurons of ALS patients

• Elevated clusterin in cerebrospinal fluid of ALS patients

• Genetic variants may modify disease progression

Prion Disease

• Clusterin is upregulated in serum and CSF in Creutzfeldt-Jakob disease

• May serve as a biomarker for prion diseases

---

Biomarker Potential

Clusterin has significant potential as a biomarker for Alzheimer’s disease ^{9Clusterin as a biomarker and therapeutic target in neurodegenerative disease2021 · Nat Rev Neurol · DOI 10.1038/s41582-020-00416-1Open reference}:

Cerebrospinal Fluid (CSF) Clusterin

• Elevated in AD patients compared to controls

• Correlates with disease severity and progression

• Levels correlate with other AD biomarkers including Aβ42, total tau, and phosphorylated tau

• Genetic variation in CLU associates with CSF biomarker levels in preclinical AD ^{2Clusterin protects against ferroptosis in Alzheimer's disease2023 · Cell Death Discov · DOI 10.1038/s41420-023-01256-w · PMID 36894631Open reference}0

Plasma Clusterin

• Associated with brain atrophy rates in AD

• May predict conversion from mild cognitive impairment (MCI) to AD

• Combined with other biomarkers improves diagnostic accuracy

• Circulating clusterin shows promise for early AD detection ^{2Clusterin protects against ferroptosis in Alzheimer's disease2023 · Cell Death Discov · DOI 10.1038/s41420-023-01256-w · PMID 36894631Open reference}1

Clinical Applications

• AD Biomarker Panel — Combined with Aβ42, tau, and p-tau improves diagnostic accuracy

• Disease Progression Marker — Tracks cognitive decline over time

• Treatment Response — Monitors therapeutic efficacy

• At-risk Identification — Identifies preclinical AD in combination with other markers

---

Therapeutic Implications

Clusterin-based Therapies

Recombinant clusterin (rCLU) is being developed as a therapeutic agent:

• Aβ Clearance — rCLU enhances amyloid clearance in preclinical models

• Neuroprotection — Protects neurons from multiple insults

• Blood-Brain Barrier Delivery — Crosses BBB, enabling CNS delivery

Gene Therapy Approaches

• CLU Overexpression — AAV-mediated CLU delivery to enhance neuroprotection

• CRISPR Editing — Correct CLU variants associated with increased AD risk

• Small Molecule Inducers — Pharmacological agents that increase clusterin expression

Small Molecule Mimetics

• Peptide Mimetics — Small molecules mimicking clusterin’s chaperone function

• Chaperone Enhancers — Compounds that enhance clusterin’s Aβ-binding affinity

---

Brain Network Connectivity

Recent neuroimaging studies have revealed that CLU genetic variants influence brain network connectivity in AD ^{2Clusterin protects against ferroptosis in Alzheimer's disease2023 · Cell Death Discov · DOI 10.1038/s41420-023-01256-w · PMID 36894631Open reference}2:

Default Mode Network (DMN) Effects

• Reduced Connectivity — CLU risk variants associated with decreased DMN connectivity

• Amyloid Relationship — Effects amplified in amyloid-positive individuals

• Clinical Correlation — Network changes correlate with cognitive performance

Tau-Clusterin Interaction

• PET Imaging Studies — CSF clusterin correlates with amyloid PET SUVr in preclinical AD ^{2Clusterin protects against ferroptosis in Alzheimer's disease2023 · Cell Death Discov · DOI 10.1038/s41420-023-01256-w · PMID 36894631Open reference}3

• Network Dysfunction — Combined tau and clusterin pathology leads to greater network disruption

---

Astrocyte-Microglia Crosstalk

Clusterin plays a critical role in mediating astrocyte-microglia communication ^{2Clusterin protects against ferroptosis in Alzheimer's disease2023 · Cell Death Discov · DOI 10.1038/s41420-023-01256-w · PMID 36894631Open reference}4:

Astrocyte-Derived Clusterin

• Microglial Activation Modulation — Astrocyte clusterin regulates microglial phenotype

• Neuroinflammatory Balance — Controls the pro-inflammatory vs. anti-inflammatory microglial states

• Phagocytic Enhancement — Promotes microglia-mediated clearance of Aβ

Therapeutic Implications

• Targeting Astrocyte Clusterin — Enhancing astrocyte clusterin production may reduce neuroinflammation

• Combination Therapy — Clusterin enhancers with anti-amyloid antibodies may improve efficacy

---

Relationship to Other AD Risk Genes

CLU interacts with several other AD risk genes:

• APOE — Both are apolipoproteins involved in lipid transport and Aβ clearance; they may have synergistic effects

• PICALM — Both were identified in the same GWAS and are involved in endocytic pathways

• BIN1 — Another GWAS gene involved in endocytosis; may converge on similar pathways

• CR1 — Another complement-related gene identified in the same GWAS

---

Brain Atlas Resources

• Allen Human Brain Atlas

• Allen Human Brain Atlas: CLU search

• Allen Mouse Brain Atlas: Clu search

• BrainSpan Atlas

Brain Region Expression Levels

Region	Expression Level	Data Source
Hippocampus	High	Human MTG
Cortex	High	Human MTG
Corpus callosum	High	Mouse Brain
Cerebellum	Medium	Mouse Brain
Substantia nigra	Medium	Mouse Brain

---

See Also

• Alzheimer’s Disease

• Amyloid-Beta Protein

• APOE Protein

• Tau Protein

• PICALM Gene

• BIN1 Gene

• Amyloid Hypothesis

• Tau Pathology

---

External Links

• NCBI Gene: CLU

• Ensembl: ENSG00000120885

• UniProt: P10909

• OMIM: 185551

• GeneCards: CLU

• GWAS Catalog: CLU

---